Prosonix, Trimel breathe easier with inhalation partnership

One company engineers pharmaceutical particles and the other makes sure the correct doses of those particles get to where they're needed when inhaled. Sounds like those two should get together--and they have. Prosonix, a UK-based firm that specializes in pharmaceutical particle engineering, and Trimel BioPharma, a Canadian-based dosing technology company, are combining their technologies for respiratory medical applications, according to In-PharmaTechnologist.

The problems plaguing inhaled medicines are nothing to sniff at. The milling process produces small enough particles, but they cannot ensure uniform amounts of the drug are inhaled and they all get to their destinations. In some cases, particles could be swallowed accidentally instead of ending up in the lungs. It can be a problem for those who suffer from asthma or cystic fibrosis.

Prosonix says it has a unique process of producing highly engineered particles and Trimel has technology to make sure the doses are uniform. Prosonix says it has 12 different companies interested, with 16 different active pharmaceutical ingredients, and also has the attention of a number of makers of generic inhalation products.

- read the In-PharmaTechnologist report

Suggested Articles

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.